Restenosis is one of the main complications in patients undergoing coronary or peripheral revascularization procedures and is the leading cause for their long-term failures. Cilostazol is the only pharmacotherapy that showed an adequate efficacy for preventing restenosis in randomized, controlled studies after coronary or peripheral revascularization procedures. The present review sums up the main clinical evidence supporting the use of cilostazol after revascularization interventions, focusing on all its benefits, warnings, and administration schedules.
|Titolo:||Restenosis after Coronary and Peripheral Intervention: Efficacy and Clinical Impact of Cilostazol|
|Appare nelle tipologie:||1.1 Articolo in rivista|